1887

Abstract

Introduction:

The therapeutic choice for treating cutaneous leishmaniasis (CL) can be difficult, notably in countries where autochthonous cases are rare. In France, CL is mostly due to imported cases. which is the endemic species in the French south-eastern region, is usually responsible for visceral leishmaniasis but rarely causes the autochthonous cutaneous form of the disease. Intralesional injection of antimonials seems to be the most recommended therapy in the latter case, but particular situations can justify the use of systemic amphotericin B (AmB).

Case presentation:

We report and illustrate a French case of locally acquired CL due to that was surprisingly unresponsive to systemic AmB, with clinical worsening and parasitic invasion of the lesion. Thereafter, the patient was successfully treated by intralesional pentavalent antimonial.

Conclusion:

This case supports the choice of intralesional therapy as the first therapeutic option in CL, an infrequent situation in France.

Loading

Article metrics loading...

/content/journal/jmmcr/10.1099/jmmcr.0.000068
2015-08-01
2021-10-23
Loading full text...

Full text loading...

/deliver/fulltext/jmmcr/2/4/jmmcr000068.html?itemId=/content/journal/jmmcr/10.1099/jmmcr.0.000068&mimeType=html&fmt=ahah

References

  1. Blum J., Desjeux P., Schwartz E., Beck B., Hatz C. 2004; Treatment of cutaneous leishmaniasis among travellers. J Antimicrob Chemother 53:158–166 [View Article][PubMed]
    [Google Scholar]
  2. Brown M., Noursadeghi M., Boyle J., Davidson R.N. 2005; Successful liposomal amphotericin B treatment of Leishmania braziliensis cutaneous leishmaniasis. Br J Dermatol 153:203–205 [View Article][PubMed]
    [Google Scholar]
  3. Buffet P.A., Rosenthal É., Gangneux J.-P., Lightburne E., Couppié P., Morizot G., Lachaud L., Marty P., Dedet J.-P., Société de Pathologie Exotique. 2011; [Therapy of leishmaniasis in France: consensus on proposed guidelines]. Presse Med 40:173–184 (in French) [View Article][PubMed]
    [Google Scholar]
  4. del Rosal T., Artigao F.B., Miguel M.J.G., de Lucas R., del Castillo F. 2010; Successful treatment of childhood cutaneous leishmaniasis with liposomal amphotericin B: report of two cases. J Trop Pediatr 56:122–124 [View Article][PubMed]
    [Google Scholar]
  5. Electronic Medicines Compendium 2015 AmBisome® Summary of Product Characteristics. http://www.medicines.org.uk/emc/medicine/1236
  6. French National Agency for Medicines and Health Products Safety 2015 [AmBisome® Summary of Product Characteristics]. http://agence-prd.ansm.sante.fr/php/ecodex/frames.php?specid = 65964911&typedoc = R&ref = R0254455.htm (in French)
  7. Goto H., Lindoso J.A.L. 2010; Current diagnosis and treatment of cutaneous and mucocutaneous leishmaniasis. Expert Rev Anti Infect Ther 8:419–433 [View Article][PubMed]
    [Google Scholar]
  8. Hervás J.A., Martín-Santiago A., Hervás D., Rojo E., Mena A., Rocamora V., Dueñas J. 2012; Old World Leishmania infantum cutaneous leishmaniasis unresponsive to liposomal amphotericin B treated with topical imiquimod. Pediatr Infect Dis J 31:97–100 [View Article][PubMed]
    [Google Scholar]
  9. Lachaud L., Dedet J.P., Marty P., Faraut F., Buffet P., Gangneux J.P., Ravel C., Bastien P., Working Group for the Notification of Human Leishmanioses in France. 2013; Surveillance of leishmaniases in France, 1999 to 2012. Euro Surveill 18:20534[PubMed]
    [Google Scholar]
  10. Maia C., Nunes M., Marques M., Henriques S., Rolão N., Campino L. 2013; In vitro drug susceptibility of Leishmania infantum isolated from humans and dogs. Exp Parasitol 135:36–41 [View Article][PubMed]
    [Google Scholar]
  11. Mary C., Faraut F., Lascombe L., Dumon H. 2004; Quantification of Leishmania infantum DNA by a real-time PCR assay with high sensitivity. J Clin Microbiol 42:5249–5255 [View Article][PubMed]
    [Google Scholar]
  12. Paradisi A., Capizzi R., Zampetti A., Proietti I., De Simone C., Feliciani C., Amerio P.L. 2005; Atypical multifocal cutaneous leishmaniasis in an immunocompetent patient treated by liposomal amphotericin B. J Infect 51:e261–e264 [View Article][PubMed]
    [Google Scholar]
  13. Rapp C., Imbert P., Darie H., Simon F., Gros P., Debord T., Roué R. 2003; [Liposomal amphotericin B treatment of cutaneous leishmaniasis contracted in Djibouti and resistant to meglumine antimoniate]. Bull Soc Pathol Exot 96:209–211 (in French)
    [Google Scholar]
  14. Rongioletti F., Cannata G.E., Parodi A. 2009; Leishmaniasis due to L. infantum presenting as macrocheilitis and responding to liposomal amphotericin B. Eur J Dermatol 19:281–282[PubMed]
    [Google Scholar]
  15. Sanofi-Aventis 2011 Glucantime® Summary of Product Characteristics. http://www.wipo.int/export/sites/www/research/en/data/sanofi/marketed_products/Glucantime.pdf
  16. Solomon M., Pavlotsky F., Leshem E., Ephros M., Trau H., Schwartz E. 2011; Liposomal amphotericin B treatment of cutaneous leishmaniasis due to Leishmania tropica . J Eur Acad Dermatol Venereol 25:973–977 [View Article][PubMed]
    [Google Scholar]
  17. WHO 2010Control of the leishmaniases. Report of a meeting of the WHO Expert Committee on the Control of Leishmaniases, Geneva, 22–26 March 2010. WHO Technical Report Series Geneva: World Health Organization;
http://instance.metastore.ingenta.com/content/journal/jmmcr/10.1099/jmmcr.0.000068
Loading
/content/journal/jmmcr/10.1099/jmmcr.0.000068
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error